Immunodeficiency Clinic
Terms & Conditions | Privacy Policy | Copyright 2010
Immunodeficiency Clinic, 585 University Avenue, Toronto, ON
Antiretroviral Interactions
Interactions with Other Drug Classes
Disclaimer
The information in this site is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Due to the rapidly changing nature of information about HIV treatment and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.
Drug Interaction Tables
Includes updates from:
-
-20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2013, Atlanta, GA
-
-11th International Congress on HIV and Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland
-
-63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA
-
-52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012, San Francisco, CA
-
-XIX International AIDS Conference, July 23-27th, 2012, Washington, DC.
Additional Information:
Tseng A, Foisy M.
Curr Infect Dis Report 2012;14(1):67-82.
Nucleoside Reverse Transcriptase Inhibitors
Non-nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors - Secondary agents (amprenavir, indinavir, nelfinavir, soft-gel saquinavir)
Hepatitis C Directly Acting Antivirals
Antiretroviral Treatment Options for Patients on DAAs - Summary
